Australia markets closed

Firebrick Pharma Limited (FRE.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.05300.0000 (0.00%)
At close: 02:05PM AEST

Firebrick Pharma Limited

440 Collins Street
Level 10
Melbourne, VIC 3000
Australia
1300 301 874
https://www.firebrickpharma.com

Sector(s)Healthcare
IndustryDrug Manufacturers - General
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Peter Laurence Molloy BSc, FAICD, MBAFounder, Executive Chairman & CEO351.3kN/A1954
Dr. Stephen Francis Goodall MASc, MBAFounder, COO & Executive Director290.56kN/AN/A
Mr. Kavi Bekarma B.Sc., C.A.Chief Financial OfficerN/AN/AN/A
Dr. Simon TuckerChief Scientific OfficerN/AN/AN/A
Prof. Peter FriedlandChief Medical OfficerN/AN/AN/A
Dr. Monique BaldwinHead of Regulatory AffairsN/AN/AN/A
Mr. Stephen BuckleyCompany SecretaryN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Firebrick Pharma Limited engages in the development and partnering of broad-spectrum antimicrobial spray for the treatment of common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.

Corporate governance

Firebrick Pharma Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.